$562.86 Million in Sales Expected for Nu Skin Enterprises (NUS) This Quarter

Wall Street analysts expect Nu Skin Enterprises (NYSE:NUS) to announce $562.86 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Nu Skin Enterprises’ earnings, with the lowest sales estimate coming in at $555.54 million and the highest estimate coming in at $570.18 million. Nu Skin Enterprises posted sales of $499.10 million in the same quarter last year, which suggests a positive year-over-year growth rate of 12.8%. The firm is expected to issue its next earnings results after the market closes on Thursday, April 26th.

On average, analysts expect that Nu Skin Enterprises will report full-year sales of $2.47 billion for the current financial year, with estimates ranging from $2.46 billion to $2.48 billion. For the next year, analysts forecast that the business will report sales of $2.54 billion per share, with estimates ranging from $2.53 billion to $2.54 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Nu Skin Enterprises.

How to Become a New Pot Stock Millionaire

Nu Skin Enterprises (NYSE:NUS) last issued its earnings results on Thursday, February 15th. The company reported $1.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.19 by $0.01. Nu Skin Enterprises had a return on equity of 25.23% and a net margin of 5.68%. The company had revenue of $666.20 million during the quarter, compared to the consensus estimate of $667.39 million. During the same quarter in the prior year, the business earned $0.79 earnings per share. The company’s revenue was up 25.4% compared to the same quarter last year.



Several equities research analysts have recently weighed in on the company. Deutsche Bank downgraded Nu Skin Enterprises from a “buy” rating to a “hold” rating and set a $77.00 target price for the company. in a research report on Friday, April 13th. ValuEngine raised Nu Skin Enterprises from a “buy” rating to a “strong-buy” rating in a report on Monday, April 2nd. Zacks Investment Research downgraded Nu Skin Enterprises from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Stifel Nicolaus increased their price target on Nu Skin Enterprises from $50.00 to $57.00 and gave the company a “sell” rating in a report on Friday, February 16th. Finally, Pivotal Research reissued a “buy” rating and issued a $90.00 price target on shares of Nu Skin Enterprises in a report on Friday, February 16th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $71.29.

In related news, Chairman Steven Lund sold 81,000 shares of the stock in a transaction dated Wednesday, April 4th. The stock was sold at an average price of $75.00, for a total value of $6,075,000.00. Following the completion of the transaction, the chairman now owns 4,769 shares of the company’s stock, valued at $357,675. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel D Matthew Dorny sold 3,000 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $72.69, for a total value of $218,070.00. Following the completion of the transaction, the general counsel now directly owns 44,399 shares of the company’s stock, valued at approximately $3,227,363.31. The disclosure for this sale can be found here. Insiders sold 104,974 shares of company stock valued at $7,810,536 in the last three months. 3.00% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in NUS. Wolverine Asset Management LLC lifted its holdings in Nu Skin Enterprises by 106.9% during the 4th quarter. Wolverine Asset Management LLC now owns 1,514 shares of the company’s stock worth $103,000 after buying an additional 23,378 shares during the last quarter. Cerebellum GP LLC bought a new position in Nu Skin Enterprises during the 4th quarter worth approximately $124,000. Amundi Pioneer Asset Management Inc. bought a new position in Nu Skin Enterprises during the 4th quarter worth approximately $192,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Nu Skin Enterprises by 38.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock worth $210,000 after buying an additional 858 shares during the last quarter. Finally, Franklin Resources Inc. bought a new position in Nu Skin Enterprises during the 4th quarter worth approximately $215,000. 76.79% of the stock is currently owned by institutional investors.

Shares of NYSE NUS traded up $0.20 on Friday, hitting $71.64. The company had a trading volume of 427,274 shares, compared to its average volume of 512,524. Nu Skin Enterprises has a 12-month low of $52.88 and a 12-month high of $76.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.74 and a quick ratio of 1.17. The company has a market capitalization of $3,750.00, a price-to-earnings ratio of 22.18, a PEG ratio of 2.06 and a beta of 1.36.

TRADEMARK VIOLATION WARNING: “$562.86 Million in Sales Expected for Nu Skin Enterprises (NUS) This Quarter” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/04/25/562-86-million-in-sales-expected-for-nu-skin-enterprises-nus-this-quarter.html.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply